| 0.5 -0.008 (-1.59%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.84 | 1-year : | 1.09 |
| Resists | First : | 0.72 | Second : | 0.93 |
| Pivot price | 0.53  |
|||
| Supports | First : | 0.37 | Second : | 0.3 |
| MAs | MA(5) : | 0.52 |
MA(20) : | 0.53 |
| MA(100) : | 0.8 |
MA(250) : | 1.2 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 22.7 |
D(3) : | 30.3 |
| RSI | RSI(14): 36 |
|||
| 52-week | High : | 2.56 | Low : | 0.37 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ EYEN ] has closed above bottom band by 15.8%. Bollinger Bands are 78.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.55 - 0.55 | 0.55 - 0.56 |
| Low: | 0.49 - 0.5 | 0.5 - 0.5 |
| Close: | 0.49 - 0.5 | 0.5 - 0.51 |
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.
Mon, 09 Sep 2024
EYEN Shares Are Trading Higher Today: What You Need To Know - Benzinga
Tue, 03 Sep 2024
Eyenovia Announces Appointment of Experienced Finance and - GlobeNewswire
Wed, 21 Aug 2024
Why Eyenovia (EYEN) Stock Is Getting Hammered Today - Benzinga
Wed, 21 Aug 2024
Eyenovia Announces Pricing of $5.14 Million Public Offering - StockTitan
Tue, 20 Aug 2024
Eyenovia, Inc. Announces Proposed Public Offering - StockTitan
Thu, 15 Aug 2024
Eyenovia (EYEN) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 77 (M) |
| Held by Insiders | 4.93e+007 (%) |
| Held by Institutions | 13.3 (%) |
| Shares Short | 2,710 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.48e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -51 % |
| Return on Assets (ttm) | 661.1 % |
| Return on Equity (ttm) | -93 % |
| Qtrly Rev. Growth | 31410 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -525.67 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -21.75 |
| Dividend | 0 |
| Forward Dividend | 2e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|